HALO News and Press, Halozyme Therapeutics Inc. From 06/29/20

The FDA approves Roche ( OTCQX:RHHBY -0.6% ) unit Genentech's subcutaneously administered Phesgo (pertuzumab, trastuzumab and hyaluronidase- zzxf) for adults with metastatic HER2-positive breast cancer and adults with early-stage HER2-positive breast cancer. More news on: Roche Holding...

Halozyme Therapeutics (NASDAQ: HALO ) will receive a $10M milestone payment from Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech triggered by the first commercial sale of subcutaneous formulation of DARZALEX (daratumumab) in the European Union. More news on: H...

SAN DIEGO , June 22, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced  the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SAN DIEGO , June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will be participating in the upcoming BMO 2020 Prescriptions for Success Healthcare Conference, which is being held as a vir...

SAN DIEGO , June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced  that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE ® in ...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with this Read more ...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

SAN DIEGO , June 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) marketing authorization for the subcutaneous (SC) formulation of DARZALEX ® (daratumumab), ...

SAN DIEGO , May 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will be participating in the following investor conferences: Jefferies Virtual Healthcare Conference at 10:00 a.m. E...